Therapeutic targeting of HO-1 has been proposed for a number of diverse diseases and conditions, and these include neurological diseases [37], acute lung injury (ALI) [38], acute kidney injury (AKI) [39,40,41], ischemia/reperfusion injuries (IRI) of multiple organs, including lung, kidney, heart, liver, and others [42,43,44], cardiovascular diseases [14,39,45,46], metabolic diseases [47,48,49,50], and cancer [29,51,52], as described in recent reviews. This evidence concerns the gene HMOX1 and acute kidney injury.